Hamamatsu University Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Hamamatsu Japan (1988)

Organization Overview

First Clinical Trial
2003
NCT00197444
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Center for Clinical Research, Hamamatsu University School of Medicine | Department Laboratory Medicine, Hamamatsu University School of Medicine | Department of Psychiatry, Hamamatsu University School of Medicine | First Department of Medicine, Hamamatsu University School of Medicine | Hamamatsu University | Hamamatsu University School of Medicien Institution Review Board | Hamamatsu University, School of Medicine, Department of Psychiatry and Neurology

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 4)

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Child Development Disorders, Pervasive (Phase 2)

Chronic Disease (Phase 4)

Communicable Diseases (Phase 3)

Duodenal Ulcer (Phase 3)

Esophageal Neoplasms (Phase 2)

Gastritis (Phase 3)

Helicobacter Infections (Phase 3)

Infections (Phase 3)

Lung Neoplasms (Phase 3)

Pneumonia (Phase 4)

Pulmonary Eosinophilia (Phase 4)

Stomach Ulcer (Phase 3)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial APIs: 26